Literature DB >> 15963076

Review article: angiogenesis soluble factors as liver disease markers.

X Salcedo1, J Medina, P Sanz-Cameno, L García-Buey, S Martín-Vilchez, R Moreno-Otero.   

Abstract

Angiogenesis is the formation of new blood vessels from pre-existing ones; it has been studied at the molecular level in different pathologies and is currently considered a promising novel therapeutic target in cancer. Recently, the use of angiogenesis soluble factors as markers of tumour growth has been investigated. The knowledge gained has led to test their use as therapeutic agents. Additionally, angiogenesis soluble factors could be used for the follow-up of pathologies that currently require monitoring with invasive techniques, like chronic viral hepatitis or renal and haematological diseases. The different factors have been described in multiple studies. In some cases, such as hepatocellular carcinoma, a potential use as prognostic markers has been suggested.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15963076     DOI: 10.1111/j.1365-2036.2005.02532.x

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  9 in total

Review 1.  Angiogenesis and liver fibrosis.

Authors:  Gülsüm Özlem Elpek
Journal:  World J Hepatol       Date:  2015-03-27

2.  Angiogenesis: a phenomenon which aggravates chronic liver disease progression.

Authors:  Michał Kukla
Journal:  Hepatol Int       Date:  2012-07-26       Impact factor: 6.047

Review 3.  Angiogenesis and Hepatic Fibrosis: Western and Chinese Medicine Therapies on the Road.

Authors:  Jing-Si Wang; Qiu-Yun Zhang; Jin-Lian Cheng; Lan-Yu Chen; Nai-Li Yao; Gui-Zhi Sun; Yu-Ling Chu
Journal:  Chin J Integr Med       Date:  2018-06-25       Impact factor: 1.978

4.  Mesenchymal stem cells promote tumor angiogenesis via the action of transforming growth factor β1.

Authors:  Guo-Cai Li; Hong-Wei Zhang; Qing-Chun Zhao; L I Sun; Jian-Jun Yang; Liu Hong; Fan Feng; Lei Cai
Journal:  Oncol Lett       Date:  2015-12-03       Impact factor: 2.967

5.  Serum levels of vascular endothelial growth factor in non-alcoholic fatty liver disease.

Authors:  Maria-Vasiliki Papageorgiou; Emilia Hadziyannis; Dina Tiniakos; Anastasia Georgiou; Aikaterini Margariti; Athanasios Kostas; George V Papatheodoridis
Journal:  Ann Gastroenterol       Date:  2016-12-01

6.  Natural health products that inhibit angiogenesis: a potential source for investigational new agents to treat cancer-Part 2.

Authors:  S M Sagar; D Yance; R K Wong
Journal:  Curr Oncol       Date:  2006-06       Impact factor: 3.677

7.  Inhibition of tyrosine kinase receptor Tie2 reverts HCV-induced hepatic stellate cell activation.

Authors:  Samuel Martín-Vílchez; Yolanda Rodríguez-Muñoz; Rosario López-Rodríguez; María Jesús Borque-Iñurrita; Francisca Molina-Jiménez; Luisa García-Buey; Ricardo Moreno-Otero; Paloma Sanz-Cameno
Journal:  PLoS One       Date:  2014-10-10       Impact factor: 3.240

8.  Curcumin attenuates angiogenesis in liver fibrosis and inhibits angiogenic properties of hepatic stellate cells.

Authors:  Feng Zhang; Zili Zhang; Li Chen; Desong Kong; Xiaoping Zhang; Chunfeng Lu; Yin Lu; Shizhong Zheng
Journal:  J Cell Mol Med       Date:  2014-04-30       Impact factor: 5.310

9.  XSSJS inhibits hepatic fibrosis by promoting the miR-29b-3p/VEGFA axis in vitro and in vivo.

Authors:  Tianyao Zhang; Yu Yang; Baojia Wang; Long Wang; Dong Wang; Ning Cao; Jinyu Shi
Journal:  Biosci Rep       Date:  2022-02-25       Impact factor: 3.840

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.